/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Study: Many Americans Say They Are More Likely to Participate in a Fitness Routine If Given Opportunity to Socialize, Earn Financial Incentives
Reading Time: 4 minutes
-
Third-annual UnitedHealthcare Wellness Checkup Survey provides
insights into people’s knowledge and opinions about various health
topics, including preferences about employer-sponsored well-being
programs -
People trying to improve their health prioritize a healthy diet,
access to routine medical care, and stopping smoking or reducing
drinking -
More than half of survey respondents said they expect to remain
healthy enough to accomplish everyday activities until 80 or older,
including 11 percent saying those tasks will “never” be an issue -
Among employees with access to a well-being program, 57 percent
said it has helped improve their health; of these, 27 percent said the
program helped detect a disease or medical condition
MINNETONKA, Minn.–(BUSINESS WIRE)–More than two-thirds of Americans say an incentive of as little as $2
per day would motivate them to devote at least an hour each day toward
improving their health, while nearly 60 percent of people say they would
be more likely to participate in a fitness routine if the program
offered an opportunity to socialize or make friends, according to a new
nationwide survey.
These are some of the findings from the 2019 UnitedHealthcare Wellness
Checkup Survey, which examines people’s opinions about health topics
and preferences, offering insights to help improve employer-sponsored
well-being or disease-management programs. The survey’s key findings
include:
-
Opportunities to socialize, earn financial incentives appeal to
many. More than half (57 percent) of survey respondents said they
would be more likely to consistently participate in a fitness routine
if the regimen provided a social component, either in-person or
virtually. Among employees with access to a well-being program, 67
percent said it was important that their significant other or family
members have the opportunity to participate, too. Across all
respondents, more than two-thirds (68 percent) said an incentive of as
little as $2 per day would motivate them to devote at least an hour
each day toward improving their health. -
Many people are optimistic about remaining healthy as they age. More
than half (53 percent) of survey respondents anticipate being able to
accomplish everyday activities until 80 or older, including 11 percent
saying those tasks will “never” be an issue. Gen Xers – defined as
people between 39 and 54 years old – were the most optimistic, with
nearly three-quarters (74 percent) expecting to maintain their health
beyond 80, including 15 percent saying health issues will never
prevent them from accomplishing everyday tasks. However, one
study concluded that 42 percent of Americans 80 or older have
functional limitations, such as the inability to walk a flight of
stairs. -
Healthy diet, access to medical care and stopping smoking top
priorities. Survey respondents considered a healthy diet, such as
eating fruits and vegetables, as the top priority when trying to
improve their health, with a mean score of 4.5 (5 being “extremely
important”). That was followed by access to routine medical care, such
as an annual physical (4.4); stopping smoking and/or reducing drinking
(4.4); getting sufficient sleep (4.3); engaging in strength or
cardiovascular training (4.3); increasing social activity (3.7); and
improving mindfulness (3.6). -
Most people underestimate the connection between lifestyle choices
and chronic conditions. About one-fifth (22 percent) of survey
respondents correctly recognized that 80
percent or more of the incidence of premature chronic conditions,
such as heart disease, stroke and diabetes, are generally caused by
modifiable lifestyle choices, such as risk factors like smoking or
obesity, as opposed to being caused by genetic factors. More than
one-third (38 percent) thought between 50 percent and 79 percent of
premature chronic conditions were caused by lifestyle choices, while
32 percent said genetics were to blame for more than half of these
diseases.
“This year employers are expected to invest an average of more than $3.6
million1 on their respective well-being programs, and over 60
percent of employees2 are interested in engaging in these
initiatives. The UnitedHealthcare Wellness Checkup Survey
provides insights that we hope can be helpful to enhance the design and
implementation of well-being programs, which may help improve employees’
health, reduce absenteeism and curb care costs,” said Rebecca Madsen,
UnitedHealthcare chief consumer officer.
Many U.S. companies are investing in wellness programs, with more than
two-thirds (67 percent) of companies planning to expand these
initiatives during the next few years, according to a recent
study by the National Business Group on Health. A separate
study published in The American Journal of Cardiology concluded that
one employer’s well-being initiative generated a six-fold return on
investment and reduced health risks for people enrolled in the program.
Many Employees Say Well-being Programs Have Improved Their Health,
Productivity
More than half (57 percent) of people with
access to wellness programs said the initiatives have made a positive
impact on their health. Of these, 82 percent said they were motivated to
pay more attention to their health; 63 percent said they increased
physical activity; 59 percent improved their diet; and 30 percent
reported improved sleep. More than one-quarter (27 percent) said the
program helped detect a disease or medical condition, while 8 percent
said they stopped smoking or using nicotine.
In regard to job performance among those who said the well-being program
made a positive impact on their health, 50 percent said the initiative
helped reduce stress; 49 percent reported improved productivity; and 35
percent said they took fewer sick days. About one-quarter (26 percent)
reported no impact on job performance.
Among employees without access to wellness programs, 70 percent of
respondents said they would be interested in such initiatives if
offered, including 43 percent who are “very interested.” More than
three-quarters (77 percent) of Gen Xers said they wanted access to a
well-being program, more so than any other age group.
About the Survey
The UnitedHealthcare Wellness Checkup
Survey was conducted April 11-15, 2019, using the Engine Telephone
CARAVAN® survey among a landline and mobile phone probability sample of
1,000 adults ages 18 and older living in the continental United States.
The margin of error was plus or minus 3.1 percent at the 95 percent
confidence level. For complete survey results, click
here.
About UnitedHealthcare
UnitedHealthcare
is dedicated to helping people live healthier lives and making the
health system work better for everyone by simplifying the health care
experience, meeting consumer health and wellness needs, and sustaining
trusted relationships with care providers. In the United States,
UnitedHealthcare offers the full spectrum of health benefit programs for
individuals, employers, and Medicare and Medicaid beneficiaries, and
contracts directly with more than 1.3 million physicians and care
professionals, and 6,000 hospitals and other care facilities nationwide.
The company also provides health benefits and delivers care to people
through owned and operated health care facilities in South America.
UnitedHealthcare is one of the businesses of UnitedHealth Group (NYSE:
UNH), a diversified health care company. For more information, visit
UnitedHealthcare at www.uhc.com
or follow @UHC on Twitter.
1 National Business Group on Health, 2019
https://www.businessgrouphealth.org/news/nbgh-news/press-releases/press-release-details/?ID=355
2 Rand Corporation, Incentives for Workplace Wellness
Programs, 2015
https://www.rand.org/content/dam/rand/pubs/research_briefs/RB9800/RR9842/RAND_RB9842.pdf
Click
here to subscribe to Mobile Alerts for UnitedHealth Group.
Contacts
Will Shanley
UnitedHealthcare
(714) 204-8005
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Innocan
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use
HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].
Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.
Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.“
Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:
“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”
About Innocan
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary note regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market
[2] https://www.cdc.gov/opioids/data/index.html
Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html
Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom
NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.
Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.
“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”
The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.
Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.
INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]
MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html
-
Cannabis2 weeks ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis2 weeks agoAvicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis2 weeks ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services
-
transfer1 week agoIMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Cannabis6 days ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis7 days ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
CCELL®1 week agoCCELL Launches Environmentally Conscious Eco Star AIO Vaporizer
